Twitter | Search | |
IOTherapyEssentials
We offer health care provider resources for optimizing Immuno-Oncology (IO) therapy.
155
Tweets
52
Following
30
Followers
Tweets
IOTherapyEssentials Nov 18
As well as our Patient Action Plans and Care Step Pathways, the Decision-Support Tool for Stage III Melanoma is now available for the Canadian audience! 🇨🇦 Find out more at .
Reply Retweet Like
IOTherapyEssentials Nov 6
"Whilst the pathogenic significance of anti-LAD-1 IgG remains unclear, it may be sufficient to precipitate the development of BP, even in the absence of anti-BP180-NC16A IgG, based on several case reports in Japanese patients." Read more at .
Reply Retweet Like
IOTherapyEssentials Nov 5
"A pooled analysis of 4 CheckMate trials showed that nivolumab may have a long-term survival benefit in patients with previously treated advanced non-small cell lung cancer (NSCLC), with an estimated 4-year survival of 14% overall.1" Read more at .
Reply Retweet Like
IOTherapyEssentials Nov 4
"We present a patient who developed seronegative MG resulting in respiratory failure while being treated with avelumab for metastatic, treatment-refractory ovarian cancer." Explore the findings at .
Reply Retweet Like
IOTherapyEssentials Nov 3
Have you checked out our HCP videos? In our series, Marianne J. Davies, IO faculty member, discusses the recognition and management of hypophysitis, adrenal insufficiency, pneumonitis and even nephritis. Check it out here ➡️ .
Reply Retweet Like
IOTherapyEssentials Nov 2
"The study findings could have important implications for clinical trial participation for people living with HIV, who have historically been excluded from trials and who have an increased risk of developing a range of cancers" Visit to read more.
Reply Retweet Like
IOTherapyEssentials Nov 1
"The purpose of this retrospective study was to identify the predictive biomarkers of response to pretreatment for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab." Read more at .
Reply Retweet Like
IOTherapyEssentials Oct 31
Would you like to have meaningful conversations with both your colleagues and the experts about the growing world that is ? Join our Facebook Q&A Community! All you have to do is search for 'Immuno-Oncology Therapy Essentials Group' on Facebook and request to join.
Reply Retweet Like
IOTherapyEssentials Oct 30
" (cemiplimab) has been conditionally approved to be sold in the European Union for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma, one of the most common types of ." Read the full story at .
Reply Retweet Like
IOTherapyEssentials Oct 30
For each therapy, our HCP Toolkit provides an overview of drug dosing and administration, side effects, clinical pearls, Q&A, patient and HCP resources, as well as specific side-effect management content! Download your free toolkits today at .
Reply Retweet Like
IOTherapyEssentials Oct 29
"The FDA action opens the door for in small cell lung cancer; the is already indicated for treatment of non-small cell lung cancer and other conditions ranging from to ." Read more at .
Reply Retweet Like
IOTherapyEssentials Oct 28
“Dermatologists are an important part of an oncology patient’s treatment team. They can help reduce pain or discomfort associated with cancer therapy and limit visible side effects, increasing the patient’s ability to continue treatment.” ➡️
Reply Retweet Like
IOTherapyEssentials Oct 28
Did you know we have organized our materials by ? From kidney and liver cancer to melanoma and Hodgkin lymphoma, we have a variety of resources to help you take the best possible care of your patients. Visit to browse them on our website.
Reply Retweet Like
IOTherapyEssentials Oct 27
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC). Read more at .
Reply Retweet Like
IOTherapyEssentials Oct 26
"The therapy carries a wide spectrum of tumor-associated neoantigens — tumor specific proteins produced after mutations in cells’ DNA — which activate the immune system toward cancer cells." Find out more at .
Reply Retweet Like
IOTherapyEssentials Oct 25
We are pleased to announce the availability of our Care Step Pathways and Patient Action Plans customized for the Canadian audience! 🇨🇦 Check them out at .
Reply Retweet Like
IOTherapyEssentials Oct 24
"Prophylactic anti-TNF therapy improves the safety and, to some degree, the efficacy of checkpoint blockade combination immunotherapies, a mouse study says." Read more at .
Reply Retweet Like
IOTherapyEssentials Oct 23
"To date, 11 patients have been vaccinated with a single dose of PolyPEPI1018 just after transitioning into maintenance therapy with Avastin (bevacizumab) and the chemotherapy fluoropyrimidine." Find out more at .
Reply Retweet Like
IOTherapyEssentials Oct 22
“The plus results from Part 1a of CheckMate-227 offers the potential for a chemo-sparing regimen that demonstrates an OS benefit to first-line treatment of patients with .” Find out more at .
Reply Retweet Like
IOTherapyEssentials Oct 20
"Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer. However, this comes at the cost of frequent immune-related adverse events." Find out more at .
Reply Retweet Like